LSLuis Miguel Helguero Santin

Luis Miguel Helguero Santin

*This is an algorithmically generated author record based on publicly available information.

Luis Miguel Helguero Santin has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Actitudes hacia la eutanasia en estudiantes peruanos de medicina y derecho: un estudio descriptivo exploratorio

    by Christopher G. Valdiviezo-Morales, Amanda Ávila-Reyes, Paolo Luna-Flores, Shirley Puse-Lozada, Luis M. Helguero-Santín

    Objective: Medical and law students, as future professionals involved in end-of-life decision-making, play an important role in discussions surrounding euthanasia. This study aimed to describe the attitudes of medical and law students toward euthanasia. Materials and methods: An exploratory descriptive study was conducted using a self-administered online survey between June and July 2021 among medical and law students aged 18 years or older. The survey was partially validated through a pilot study and included a standardized definition of euthanasia as guidance, followed by nine questionnaire items. Results were summarized using absolute and relative frequencies. Results: A total of 240 participants were included, with a median age of 21 years. Most participants were female (54.6%), 62.1% were medical students, and 69.6% identified as Catholic. Overall, 50.8% considered euthanasia ethically acceptable, and 42.5% supported its legalization for all age groups, including children. More favorable attitudes toward euthanasia were observed in cases involving terminal incurable illness (78.3%), severe health conditions (70.0%), and unbearable pain without relief (60.0%). Conclusions: Favorable attitudes toward euthanasia predominated in both groups, with higher levels of acceptance observed among law students. As this was an exploratory study, the findings are not generalizable; however, they may serve as a basis for future research.

  • Open Access

    Persistencia del conducto onfalomesentérico en un lactante. A propósito de un caso

    by Juan Carlos Montes-Chávez, Luis Helguero-Santin

    La persistencia del conducto onfalomesentérico es una anomalía congénita rara. La secreción umbilical persistente es un hallazgo que puede presentarse en neonatos y lactantes, y si bien en algunos casos responde al tratamiento médico, en otros requiere una intervención quirúrgica. Presentamos el caso de un lactante de dos meses diagnosticado al nacer de un granuloma umbilical, cuya sintomatología persistió pese al tratamiento con nitrato de plata. Debido a la falta de mejoría clínica, se realizó una laparotomía exploradora, identificándose un conducto onfalomesentérico permeable. Se procedió a la resección del segmento afectado y anastomosis del íleon. El paciente presentó una evolución postoperatoria favorable y fue dado de alta cinco días después del procedimiento. Este caso destaca la relevancia de considerar esta entidad en el diagnóstico diferencial de afecciones umbilicales aparentes, dado que puede simular lesiones benignas y dificultar su identificación temprana.

  • Diabetes care quality according to facility setting: A cross-sectional analysis in six Peruvian regions

    by Jorge R. Calderon-Ticona, Alvaro Taype-Rondan, Georgina Villamonte, L. Max Labán-Seminario, Luis M. Helguero-Santín, J. Jaime Miranda, Maria Lazo-Porras


  • Open Access

    Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country

    by Edward Mezones-Holguin, Rocio Violeta Gamboa-Cardenas, Gadwyn Sanchez-Felix, José Chávez-Corrales, Luis Miguel Helguero-Santin, Luis Max Laban Seminario, Paula Alejandra Burela-Prado, Maribel Marilu Castro-Reyes, Fabian Fiestas

    Introduction: Biological products, including infliximab (INF), are a therapeutic option for various medical conditions. In the Peruvian Social Security (EsSalud), infliximab is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthropathy, ankylosing spondylitis, ulcerative colitis and Crohn’s disease (in cases refractory to conventional treatment). Biosimilars are a safe and effective alternative approved for these diseases in patients who start treatment with infliximab. Nevertheless, there are people in treatment with the biological reference product (BRP), in whom the continuing therapy with a biosimilar biological product (BBP) must be evaluated. Objectives: To synthesize the best available evidence, calculate a preliminary financial impact and conduct technical discussions about the interchangeability into biosimilar in patients receiving treatment with original infliximab for medical conditions approved in EsSalud. Methodology: We carried out a systematic review of controlled clinical trials. Primary search was performed in Pubmed- MEDLINE, SCOPUS, WOS, EMBASE, TRIPDATABASE, DARE, Cochrane Library, NICE, AHRQ, SMC, McMaster-PLUS, CADTH, and HSE until June-2018. We used the Cochrane Collaboration tool to assess the risk of bias. Also, we implemented a preliminary financial analysis about the impact of biosimilar introduction on institutional purchasing budget. Moreover, technical meetings with medical doctors specialized in rheumatology, gastroenterology and dermatology were held for discussing findings. Results: In primary search, 1136 records were identified, and 357 duplicates were removed. From 799 records, we excluded 765 after title and abstract evaluation. From 14 full-text appraised documents, we included five clinical trials in the risk of bias assessment: four studies evaluated CTP-13 and one tested SB2. Two double-blind clinical trials reported no differences in efficacy and safety profiles between maintenance group (INF/INF) and interchangeability group in all diseases included (INF/CTP-13) and rheumatoid arthritis (CTP13 and SB2). In the other three studies, open-label extension of primary clinical trials, no differences were founded in efficacy and safety profiles between CTP-13/CTP-13 and INF/CTP-13 groups. In financial analysis, the inclusion of biosimilars implied savings around S/7´642,780.00 (1USD=S/3.30) on purchasing budget of EsSalud. In technical meetings, beyond certain concerns, specialists agreed with the findings. Conclusions: Evidence from clinical trials support that there are no differences in efficacy or safety of continuing the treatment with Infliximab BRP or exchanging into its biosimilar in patients with medical conditions approved in EsSalud. Financial analysis shows that the biosimilar introduction produce savings in purchasing institutional budget. Therefore, based on cost-opportunity principle, exchanging into biosimilar in patients receiving the original Infliximab, is a valid therapeutic alternative in the Peruvian Social Security.


  • Top Cited Papers
    Open Access

    Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

    by Aneel Bhangu, Adesoji O Ademuyiwa, Maria Lorena Aguilera, Philip Alexander, Sara W Al-Saqqa, Giuliano Borda-Luque, Ainhoa Costas-Chavarri, Thomas M Drake, Faustin Ntirenganya, J Edward Fitzgerald, et al.


  • Open Access

    Geographic differences in overweight and obesity prevalence in Peruvian children, 2010–2015

    by J. Smith Torres-Roman, Diego Urrunaga-Pastor, Jose L. Avilez, Luis M. Helguero-Santin, German Malaga

    Childhood obesity is emerging as a major public health problem worldwide. To date, most studies of obesity and overweight in Peru are focused on adults, with few of them involving children, a population at a critical stage of development. The trend in overweight and obesity prevalence in Peruvian children under the age of five has not yet been determined. Thus, the objective of the present study is to evaluate the prevalence rates of overweight and obesity between 2010 and 2015 in children under the age of five, stratified by geographical areas in Peru. Data were obtained from the Nutritional Status Information System of Peru. The total number of children evaluated was 14,155,914. For the Geographic Information Systems (GIS), the program Geo Da 1.8® was used to ascertain the spatial distribution of prevalence rates and was mapped for children under five. To assess the degree of spatial dependence, exploratory spatial data analysis was performed using the Moran’s I statistic and was assessed with the Local Indicators of Spatial Association (LISA) analysis to identify geographic concentrations of high and low of obesity and overweight levels. Between 2010 and 2015, the national prevalence of childhood overweight and obesity ranged from 6.2%- 6.8% and 1.5%–2.7%, respectively. The highest prevalence of childhood overweight and obesity was found in 2014 and 2013, respectively. During these years, we observed that obesity decreased, but overweight remained stable. The highest prevalence of overweight and obesity was found in the departments located on the coast. Significant positive spatial autocorrelation was found for both overweight and obesity. The departments with the highest prevalence of overweight and obesity were concentrated in Lima, Callao, Ica, Moquegua and Tacna. The lowest were found in Loreto, Cusco and San Martin. The decrease in obesity and the stabilisation of overweight are positive results for the Peruvian childhood. However, in comparison with other Latin American countries, Peru still lags in obesity prevention.


    • 1 March 2018
      • Vol. 26  (1) , 28-36

    Research trends in Carrion's disease in the last 60 years. A bibliometric assessment of Latin American scientific production.

    by Carlos Culquichicón, Emanuel Ramos-Cedano, Luis Helguero-Santin, Roberto Niño-Garcia, Alfonso J Rodriguez-Morales

    Carrion's disease is a major re-emerging and occupational health disease. This bibliometric study aimed to evaluate scientific production on this disease both globally and in Latin America. SCI-E, MEDLINE/GoPubMed, SCOPUS, ScIELO, and LILACS databases were searched for Carrion's disease-related articles. They were classified according to publication year, type, city and institution of origin, international cooperation, scientific journal, impact factor, publication language, author(s), and H-index. There were 170 articles in SCI-E. The USA was the largest contributor (42.9%), followed by Peru (24.1%) and Spain (12.4%). Latin American publications were cited 811 times (regional H-index=18). There were 335 articles in SCOPUS: 25.9%, 11.6%, and 8.3% were published by the USA, Peru, and Spain, respectively. Latin American publications were cited 613 times (H-index=12): Peru, Colombia, and Brazil received the most citations (n=395, H-index=10; n=61, H-index=1; and n=54, H-index=4, respectively). The most scientifically productive American institution was the University of Montana (2.9% of American production). In Peru, it was the Institute of Tropical Medicine Alexander von Humboldt of Peruvian University Cayetano Heredia (6.5% of Peruvian scientific production). There were 3,802 articles in Medline (1.2% were Peruvian), 35 in SciELO (94.3% were from Peru), and 168 in LILACS (11% were published in 2010-2014; only one article was published in 2015). Scientific production worldwide is led by the USA, and, in Latin America, by Peru and Brazil. However, Latin American scientific production in bibliographic databases is much lower than in other regions, despite being an endemic area for Carrion's disease.


  • O-19 Relationship Between Age and Degree of Involvement of the Corpora Cavernosa in Elastography in Patients with Erectile Dysfunction. First Experience in Peru

    by J. Saldaña-Gallo, L.M. Helguero-Santin, J.A. Grandez-Urbina, J.S. Torres-Roman, R. Pichardo-Rodriguez, G. Espejo-Zarate, K. Verde-Guerra

  • O-20 Association Between Age and Pathological Venous Leakage in Patients with Erectile Dysfunction at a Urological Clinic in Peru

    by J. Saldaña-Gallo, J.A. Grandez-Urbina, L.M. Helguero-Santin, R. Pichardo-Rodriguez, J.S. Torres-Roman, K. Verde-Guerra, G. Espejo-Zarate

  • Regional and departmental analysis of mortality rates for prostate cancer in Peru, 2005-2014

    by J.S. Torres Roman, L.M. Helguero-Santin, J.A. Grandez-Urbina, R. Pichardo-Rodriguez, J. Saldaña-Gallo